This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Paisley, S Articles by Wight, J Search for Related Content PubMed PubMed Citation Articles by Paisley, S Articles by Wight, J Pubmed/NCBI databases Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review

The School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield S1 4DA, UK

S Beard

The School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield S1 4DA, UK

A Hunn

The School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield S1 4DA, UK

J Wight

The School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield S1 4DA, UK, j.p.wight{at}shef.ac.uk

Spasticity is a common disabling feature of multiple sclerosis. A variety of drugs are in regular use as oral treatment, including baclofen, dantrolene, tizanidine, and diazepam. Published evidence of effectiveness is limited. Most trials are of small size, of short duration, and have not reported on functional outcomes. Studies have been published which suggest that baclofen, tizanidine, and diazepam are all effective in reducing clinical measures of spasticity, but there is little evidence that they lead to an improvement in patient function. There is no evidence to suggest any difference in effectiveness between them. The evidence that dantrolene has any effect on spasticity is of poor quality. Diazepam and dantrolene are associated with more side effects than baclofen and tizanidine. There is evidence for the effectiveness of gabapentin in reducing spasticity and improving function in the short term, though longer-term studies are needed to establish its true value. One randomized controlled trial of threonine does not support its effectiveness.

Key Words: baclofen • dantrolene • diazepam • gabapentin • multiple sclerosis • spasticity • systematic review • threonine • tizanidine

Multiple Sclerosis, Vol. 8, No. 4, 319-329 (2002)
DOI: 10.1191/1352458502ms795rr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Crayton, R. A. Heyman, and H. S. Rossman A multimodal approach to managing the symptoms of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S12 - S18. [Abstract] [Full Text]

				E. Montane, A. Vallano, and J. R. Laporte Oral antispastic drugs in nonprogressive neurologic diseases: A systematic review Neurology, October 26, 2004; 63(8): 1357 - 1363. [Abstract] [Full Text] [PDF]

				M A Rizzo, O C Hadjimichael, J Preiningerova, and T L Vollmer Prevalence and treatment of spasticity reported by multiple sclerosis patients Multiple Sclerosis, October 1, 2004; 10(5): 589 - 595. [Abstract] [PDF]